12H-indolo[2,3-a]quinolizin-5-ylium | 239-17-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 12H-indolo[2,3-a]quinolizin-5-ylium
• 英文别名: deethylflavopereirine；Desaethylflavopereirin；12H-Indolo[2,3-a]quinolizin-5-ium
• CAS: 239-17-8
• 化学式: C₁₅H₁₁N₂
• 分子量: 219.266
• InChiKey: CMLQXZNMSSZRCH-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  19.9
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  12H-indolo[2,3-a]quinolizin-5-ylium 在 硫酸 作用下， 以 甲醇 为溶剂， 生成 12H-indolo[2,3-a]quinolizin-5-ylium sulfate
  参考文献：
  名称：

  WO2019191776A5

  摘要：

  公开号：

  WO2019191776A5
• 作为产物：
  描述：

  1,2,3,4,6,7-hexahydro-12H-indolo<2,3-a>quinolizin-5-ium perchlorate 在 palladium 10% on activated carbon 作用下， 生成 12H-indolo[2,3-a]quinolizin-5-ylium
  参考文献：
  名称：

  WO2019191776A5

  摘要：

  公开号：

  WO2019191776A5

文献信息

• 1,1-Disubstituted-hexahydro-indolo(2,3-a)quinolizine derivatives and their use in the enantioselective synthesis of optically active 14-oxo-E-homo-eburnane derivatives
  申请人：RICHTER GEDEON VEGYESZETI GYAR R.T.

  公开号：EP0050492A1

  公开（公告）日：1982-04-28

  Compounds of general formula (A), wherein R1 represents a C1-4 alkyl group; X represents a residue of an acid; either B represents a group -COOR2 (in which R2 represents a C1-4 alkyl group) and Z represents a group (in which R3 and R5, which may be the same or different, each represents a C1-4 alkyl radical) or B represents a group -COOH or a hydrogen atom and Z represents a group -CH2COOH, of use in the enantioselective synthesis of optically active 14-oxo-E-homo-eburnane derivatives.

  通式（A）化合物，其中 R1 代表 C1-4 烷基；X 代表酸的残基；B 代表基团 -COOR2（其中 R2 代表 C1-4 烷基）和 Z 代表基团（其中 R3 和 R5 可以相同或不同，各自代表 C1-4 烷基）或 B 代表基团 -COOH 或氢原子和 Z 代表基团 -CH2COOH，用于光学活性 14-氧代-E-高本烷衍生物的对映选择性合成。
• Selective anti-cancer agent effective for prevention and treatment
  申请人：Molecular International Research, Inc.

  公开号：US11083714B2

  公开（公告）日：2021-08-10

  De-ethylflavopereirine, a pharmaceutically acceptable salt thereof, a solvate or a hydrate thereof, or a pharmaceutically acceptable salt of a solvate or a hydrate thereof may be used as cancer therapy (i.e., prevention and/or treatment) in a subject in need thereof, including a pathological condition such as inflammation, especially chronic, or cancer (e.g., a carcinoma, a sarcoma, a melanoma, a leukemia, a lymphoma), especially a solid tumor and/or a metastasis thereof. In particular, systemic administration of such improved anti-cancer agents in effective amounts may selectively destroy cancer cells (including cancer stem cells) in a solid tumor and/or at a site of metastasis. They are well-tolerated by the subject, even at large systemic doses and their resulting high concentrations in the circulation, and provide safe and effective anti-cancer agents.

  去乙基氟派瑞林、其药学上可接受的盐、其溶液剂或水合物、或其溶液剂或水合物的药学上可接受的盐可用于有需要的受试者的癌症治疗（即预防和/或治疗），包括诸如炎症（尤其是慢性炎症）或癌症（如癌、肉瘤、黑色素瘤、白血病、淋巴瘤）（尤其是实体瘤和/或转移瘤）等病理状况。特别是，全身给药有效量的这种改良抗癌剂可以选择性地破坏实体瘤和/或转移部位的癌细胞（包括癌症干细胞）。受试者对它们的耐受性良好，即使是大剂量的全身用药及其在血液循环中产生的高浓度，也能提供安全有效的抗癌剂。
• FLAVOPEREIRINE DERIVATIVES FOR CANCER THERAPY
  申请人：DABUR PHARMA LTD.

  公开号：EP1758904B1

  公开（公告）日：2009-06-03
• SELECTIVE ANTI-CANCER AGENT EFFECTIVE FOR PREVENTION AND TREATMENT
  申请人：Molecular International Research, Inc.

  公开号：EP3773582A1

  公开（公告）日：2021-02-17
• Flavopereirine derivatives for cancer therapy
  申请人：SESHAGIRI Venkatachalam

  公开号：US20100256177A1

  公开（公告）日：2010-10-07

  The present invention relates to novel derivatives of flavopereirine and methods for manufacture thereof. The novel derivatives of flavopereirine are useful for inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention more specifically relates to the use of derivatives of flavopereirine for the inhibition and/or prevention of cancer of the ovary, breast, prostate, pancreas, oral cavity, lung, colon, and larynx.